Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +4.84%8 Market Cap is $1,845.06 Mil as of Aug. 03, 2026. GuruFocus rates ALMR with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 863 Medical Devices & Instruments companies, Alamar Biosciences ranks better than 86.1% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alamar Biosciences's share price for the quarter that ended in Dec. 2025 was $0. Alamar Biosciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 66.52 Mil. Therefore, Alamar Biosciences's market cap for the quarter that ended in Dec. 2025 was $0.00 Mil.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alamar Biosciences's Enterprise Value for Today is $1,886.03 Mil.
Alamar Biosciences (NAS:ALMR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Alamar Biosciences Market Cap Related Terms
Alamar Biosciences Market Cap Historical Data
* Premium members only.
The historical data trend for Alamar Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences Market Cap Chart
Alamar Biosciences Annual Data
Trend
Dec24
Dec25
Market Cap
0.00
0.00
Alamar Biosciences Semi-Annual Data
Dec24
Dec25
Market Cap
0.00
0.00
ALMR vs UFPT, BFLY, ENOV: Market Cap Comparison
For the Medical Devices subindustry, Alamar Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Alamar Biosciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences (ALMR) has a Market Cap of $1,845.06 Mil as of Aug. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alamar Biosciences and its competitors. According to the industry distribution chart, Alamar Biosciences ranks #120 out of 863 companies in the Medical Devices & Instruments industry, placing it in the top 13.9%.
Is Alamar Biosciences' Market Cap too high?
Alamar Biosciences' current Market Cap is $1,845.06 Mil. The Medical Devices & Instruments industry median Market Cap is 112.48. Alamar Biosciences' value of $1,845.06 Mil is 1540.4% above this industry median. Based on the distribution chart, Alamar Biosciences ranks #120 out of 863 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Alamar Biosciences has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Market Cap compare to UFPT and BFLY?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #120 out of 863 companies for Market Cap. This places Alamar Biosciences in the top 14% of its industry — outperforming the majority of peers. The industry median Market Cap is 112.48. Alamar Biosciences' value of $1,845.06 Mil is 1540.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 112.48, based on 863 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alamar Biosciences's current Market Cap of $1,845.06 Mil is 1540.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alamar Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 112.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current Market Cap is $1,845.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Market Cap of $1,845.06 Mil. The current Market Cap is $1,845.06 Mil and 1540.4% above the Medical Devices & Instruments industry median of 112.48. Alamar Biosciences' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Market Cap is $1,845.06 Mil as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
8GF Score
Get the complete analysis for ALMR
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
